Sun Pharma Advanced Research Company Limited (NSE:SPARC)
India · Delayed Price · Currency is INR 169.50
-3.59 (-2.07%)
May 11, 2026, 10:20 AM IST
Sun Pharma Advanced Research Company Earnings Call Transcripts
Fiscal Year 2026
-
Pipeline is now focused on oncology and immunology, with lead programs in MUC1 ADC and SCD153 advancing through clinical trials. Cost optimization and partnerships support progress, while key regulatory and financial milestones are expected over the next year.
Fiscal Year 2024
-
Portfolio now centers on oncology and immunology, with SCD-153 and SBO-154 as lead assets. Multiple short-term cash catalysts are being pursued, including Sezaby exclusivity, PRV litigation, and asset partnerships. Key clinical milestones for SCD-153 and SBO-154 are set for FY25–27.